基于iCBCT分析鼻咽癌自适应放疗过程中腮腺实际体积、位置和剂量的变化OA
Actual changes in volume,position and dose of parotid glands during adaptive radiotherapy for nasopharyngeal carcinoma were analyzed based on iCBCT
背景与目的:放疗尤其是调强适形放疗(intensity-modulated radiation therapy,IMRT)已成为鼻咽癌(nasopharyngeal carcinoma,NPC)的标准根治性治疗手段,其通过精准的剂量分布提高肿瘤局部控制率并降低危及器官(organ at risk,OAR)的受照剂量,从而改善患者的生存质量.但在治疗过程中,腮腺等OAR的体积和位置可能发生显著变化,导致实际受照剂量偏离计划,从而增加不良反应的发生风险.自适应放疗(adaptive radiotherapy,ART)通过实时影像评估并调整计划,能够有效地优化剂量分布.本研究基于Halcyon加速器获取的迭代锥形束计算机断层扫描(iterative cone beam computed tomography,iCBCT)影像数据,系统分析腮腺体积、位置和受照剂量随放疗分次累加的变化规律,旨在为优化NPC放疗实践、减少腮腺损伤提供数据支持和理论依据.方法:回顾性选取2018年1月—2022年12月在江苏省肿瘤医院接受治疗的NPC患者,记录并比较治疗前后体重变化;在患者每天治疗前的iCBCT图像上勾画腮腺,分析腮腺体积的绝对与相对减少值、缩小速率及质心位移,并评估腮腺向中线的位移与其体积缩小程度的相关性.同时在Eclipse计划系统中,获得整个疗程中腮腺的实际累积受照剂量,并探究剂量变化与腮腺体积、位移的相关性.所有统计学分析均使用R语言(版本4.5.1)在RStudio集成开发环境(版本2025.05)中完成,采用Wilcoxon符号秩检验进行配对比较,采用Spearman秩相关进行相关性分析.结果:放疗期间,所有患者体重整体呈显著下降趋势,中位下降幅度为4.68%.整个NPC放疗期间,左、右侧腮腺体积分别减小为原体积的53.97%、58.34%,两侧腮腺均出现不同程度的位置改变.左侧腮腺向中线、头侧和面侧移动的比例分别为32(68.09%)、25(53.19%)和23(48.94%),右侧腮腺分别为28(59.57%)、35(74.47%)和24(51.06%).进一步分析表明,向中线移动的患者中,15分次内的位移更为显著;而向头侧和面侧移动的患者中,15分次前后的位移差异不显著.统计学检验结果也证实,两侧腮腺在X轴方向上的位置,在治疗至第15分次时已与初始计划相比产生显著改变.腮腺向中线靠拢与腮腺体积减小呈正相关性.左、右侧腮腺的平均受照剂量(mean dose,Dmean)、50%体积受照剂量(dose to 50%of the volume,D50)增大病例数分别为20例(42.55%)、17例(36.17%),在增大的病例中,左侧腮腺Dmean和D50分别增大了21.3%和24.8%,右侧腮腺分别增大了13.7%和22.2%.左、右侧腮腺Dmean前期(15分次内)增长温和,普遍在5%左右,极少患者超过120%;后期(15分次后)增长显著加速,幅度集中在15%~20%.通过分次对比各个分割照射区段间的Dmean与D50相对变化发现,主要在15分次后,存在明显的受照剂量相对增加,左侧腮腺在16~20、21~25和30分次后,相比于上次受照剂量,Dmean分别提高2.2%(24.2 Gy)、4.6%(24.8 Gy)和6.9%(26.1 Gy),D50分别提高2.1%(22.0 Gy)、5.6%(22.5 Gy)和9.6%(24.0 Gy);右侧腮腺在 21~25、30 分次后,Dmean分别提高 3.8%(25.3 Gy)、4.1%(26.0 Gy),D50 分别提高 6.5%(23.3 Gy)、9.7%(24.5 Gy).左侧腮腺Dmean和D50与其质心向中线结构靠拢的相关性为0.72和0.70,右侧腮腺Dmean和D50与其质心向中线结构靠拢的相关性为0.63和0.67.结论:腮腺在整个放疗过程中,体积减小且向中线高剂量区靠拢,腮腺受照剂量变化与腮腺质心向中线结构靠拢有关,腮腺体积变小并不一定引起腮腺受照剂量增加,且主要受照剂量的增加集中在15分次后,因此较早重新计划可控制腮腺在整个放疗中受照剂量的增加.
Background and purpose:Radiation therapy,particularly intensity-modulated radiation therapy(IMRT),has become the standard radical treatment for nasopharyngeal carcinoma(NPC).It enhances local tumor control and reduces the radiation dose to organ at risk(OAR)through precise dose distribution,thereby improving patients'quality of life.However,during the treatment process,the volume and position of OAR such as the parotid gland may undergo significant changes,leading to deviations between the actual delivered dose and the planned dose,which increases the risk of adverse reactions.Adaptive radiotherapy(ART)effectively optimizes dose distribution by assessing and adjusting the treatment plan in real-time based on imaging.This study systematically analyzes the changes in the volume,position and radiation dose of the parotid gland with the accumulation of radiotherapy fractions,using iterative cone beam computed tomography(iCBCT)imaging data obtained from a Halcyon linear accelerator.The findings provide data support and a theoretical basis for optimizing radiotherapy practices for NPC and reducing parotid gland damage.Methods:NPC patients who were treated at Jiangsu Cancer Hospital from January 2018 to December 2022 were retrospectively enrolled.The body weight before and after treatment was recorded and compared.The parotid glands were contoured on the daily pre-treatment iCBCT images to analyze the absolute and relative volume reduction,shrinkage rate,and centroid displacement of the parotid glands.The correlation between medial displacement of the parotid glands and the extent of volume shrinkage was also assessed.Additionally,the actual cumulative radiation dose to the parotid glands over the entire treatment course was obtained using the Eclipse treatment planning system,and the correlation between dose variations and parotid gland volume changes or displacement was investigated.All statistical analyses were performed using the R language(version 4.5.1)within the RStudio integrated development environment(version 2025.05).Paired comparisons were conducted using the Wilcoxon signed-rank test,and Spearman rank correlation was employed for correlation analysis.Results:During radiotherapy,the overall trend in patient body weight was a decrease,with a statistically significant median reduction of 4.68%.Throughout the entire course of radiotherapy for NPC,the volumes of the left and right parotid glands decreased to 53.97%and 58.34%of their original volumes,respectively,and both glands exhibited positional changes to varying degrees.Specifically,the proportions of left parotid glands that moved medially,cranially,and anteriorly were 32(68.09%),25(53.19%)and 23(48.94%),respectively,while the corresponding proportions for the right parotid gland were 28(59.57%),35(74.47%)and 24(51.06%).Further analysis indicated that among patients with medial displacement,the shift was more pronounced within the first 15 treatment fractions;whereas for patients with cranial or anterior displacement,the difference in displacement before and after 15 fractions was not significant.Statistical test results also confirmed that the positions of both parotid glands along the X-axis had changed significantly by the 15th fraction compared to the initial plan.A positive correlation was observed between medial displacement and volume reduction of the parotid glands.The number of cases with an increase in mean dose(Dmean)and dose to 50%of the volume(D50)for the left and right parotid glands was 20(42.55%)and 17(36.17%),respectively.Among these cases,the left Dmean and D50 increased by 21.3%and 24.8%,while the right Dmean and D50 increased by 13.7%and 22.2%,respectively.The Dmean for both left and right parotid glands showed a mild increase in the early stage(before the 15th fraction),generally around 5%,with very few patients exceeding 120%.In the later stage(after the 15th fraction),the increase accelerated significantly,primarily ranging between 15%and 20%.By comparing the relative changes in Dmean and D50 across different fractionation intervals,we also found a notable relative increase in the delivered dose,primarily after the 15th fraction.For the left parotid gland,during fractions 16-20,21-25 and after the 30th fraction,Dmean increased by 2.2%(24.2 Gy),4.6%(24.8 Gy)and 6.9%(26.1 Gy)compared to the previous interval,respectively,while D50 increased by 2.1%(22.0 Gy),5.6%(22.5 Gy)and 9.6%(24.0 Gy),respectively.For the right parotid gland,during fractions 21-25 and after the 30th fraction,Dmean increased by 3.8%(25.3 Gy)and 4.1%(26.0 Gy)compared to the previous interval,while D50 increased by 6.5%(23.3 Gy)and 9.7%(24.5 Gy),respectively.The correlations between changes in Dmean and D50 for the left parotid glands and the medial displacement of their centroids were 0.72 and 0.70.The correlations between changes in Dmean and D50 for the right parotid glands and the medial displacement of their centroids were 0.63 and 0.67.Conclusion:During the entire radiotherapy process,the parotid glands decreased in volume and moved closer to the midline high-dose region.The changes in the radiation dose received by the parotid glands were related to the movement of their centroids toward the midline structures.A reduction in parotid gland volume did not necessarily lead to an increase in the radiation dose received by the parotid glands,and the main increase in radiation dose occurred after 15 fractions.Therefore,early replanning can help control the increase in radiation dose received by the parotid glands throughout radiotherapy.
朱海港;殷欣昊;陈小四;王藤;曾强;高瀚;尹丽
江苏省肿瘤医院放射肿瘤科,江苏 南京 210009||南京医科大学第四临床学院,江苏 南京 211166||马鞍山市当涂县人民医院放射肿瘤科,安徽 马鞍山 243100江苏省肿瘤医院放射肿瘤科,江苏 南京 210009||南京医科大学第四临床学院,江苏 南京 211166||南京医科大学环境基因组学教研室,江苏省恶性肿瘤生物标志物与防治重点实验室,癌症个体化医学协同创新中心,江苏 南京 210009马鞍山市当涂县人民医院放射肿瘤科,安徽 马鞍山 243100徐州医科大学第二附属医院放射肿瘤科,江苏 徐州 221006江苏省肿瘤医院放射肿瘤科,江苏 南京 210009江苏省肿瘤医院放射肿瘤科,江苏 南京 210009江苏省肿瘤医院放射肿瘤科,江苏 南京 210009||南京医科大学第四临床学院,江苏 南京 211166||南京医科大学环境基因组学教研室,江苏省恶性肿瘤生物标志物与防治重点实验室,癌症个体化医学协同创新中心,江苏 南京 210009
医药卫生
自适应放疗鼻咽癌腮腺几何学变化剂量变化
Adaptive radiotherapyNasopharyngeal carcinomaParotid glandGeometric changeDosimetric change
《中国癌症杂志》 2026 (3)
239-250,12
肿瘤个体化医学协同创新中心恒瑞医药临床研究基金(JZ21449020210616). Personalized Medicine Collaborative Innovation Center for Cancer and Tumors Hengrui Pharmaceuticals Clinical Research Fund(JZ21449020210616).
评论